The estimated Net Worth of Kim Janda is at least $333 Tisíc dollars as of 27 December 2021. Kim Janda owns over 3,000 units of Sorrento Therapeutics Inc stock worth over $60 and over the last 14 years he sold SRNE stock worth over $0. In addition, he makes $332,650 as Director at Sorrento Therapeutics Inc.
Kim has made over 5 trades of the Sorrento Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 3,000 units of SRNE stock worth $12,000 on 27 December 2021.
The largest trade he's ever made was exercising 42,357 units of Sorrento Therapeutics Inc stock on 27 September 2021 worth over $89,373. On average, Kim trades about 2,648 units every 81 days since 2011. As of 27 December 2021 he still owns at least 6,000 units of Sorrento Therapeutics Inc stock.
You can see the complete history of Kim Janda stock trades at the bottom of the page.
Dr. Kim D. Janda Ph.D. serves as Director of the Company. Dr. Janda has served as Ely R. Callaway, Jr. Chaired Professor in the Departments of Chemistry, Immunology and Microbial Science at The Scripps Research Institute since 1996 and as the Director of the Worm Institute of Research and Medicine (WIRM) at The Scripps Research Institute since 2005. Furthermore, Dr. Janda has served as a Skaggs Scholar within the Skaggs Institute of Chemical Biology, also at The Scripps Research Institute, since 1996. Dr. Janda holds a B.S. degree from the University of South Florida in Clinical Chemistry and a doctoral degree from the University of Arizona with Robert B. Bates in natural product total synthesis. A hallmark of his research is that Dr. Janda has been able to uniquely combine principles of medicinal chemistry together with modern molecular biology, immunology and neuropharmacology, allowing the creation of both synthetic/natural molecules and processes with biological, chemical and physical properties. Dr. Janda has published over 425 original publications in refereed journals and founded the biotechnological companies CombiChem, Drug Abuse Sciences and AIPartia. Dr. Janda is associate editor of Bioorg & Med. Chem., PloS ONE and serves, or has served, on numerous journals including J. Comb. Chem., Chem. Reviews, J. Med. Chem., The Botulinum Journal, Bioorg. & Med. Chem. Lett., and Bioorg. & Med. Chem. Over a career of almost 25 years, Dr. Janda has provided numerous seminal contributions and is considered one of the first scientists to merge chemical and biological approaches into a cohesive research program. Dr. Janda serves on the Scientific Advisory Boards of Materia, Inc. and Singapore Ministry of Education (MOE), EP1 Physical Sciences.
As the Director of Sorrento Therapeutics Inc, the total compensation of Kim Janda at Sorrento Therapeutics Inc is $332,650. There are 4 executives at Sorrento Therapeutics Inc getting paid more, with Jaisim Shah having the highest compensation of $10,971,100.
Kim Janda is 63, he's been the Director of Sorrento Therapeutics Inc since 2020. There are 2 older and 10 younger executives at Sorrento Therapeutics Inc. The oldest executive at Sorrento Therapeutics Inc is Dr. Michael A. Royal, 67, who is the SVP & Chief Medical Officer.
Kim's mailing address filed with the SEC is C/O SORRENTO THERAPEUTICS, INC., 4955 DIRECTORS PLACE, SAN DIEGO, CA, 92121.
Over the last 15 years, insiders at Sorrento Therapeutics Inc have traded over $17,198,839 worth of Sorrento Therapeutics Inc stock and bought 10,353,437 units worth $10,703,222 . The most active insiders traders include Jane Ph D Hsiao, Edgar Lee a Patrick Chan Soon Shiong Fa.... On average, Sorrento Therapeutics Inc executives and independent directors trade stock every 60 days with the average trade being worth of $2,947. The most recent stock trade was executed by Henry Ji on 7 September 2022, trading 88,888 units of SRNE stock currently worth $179,554.
sorrento therapeutics is an antibody-centric, clinical stage biopharmaceutical company developing new treatments for cancer, inflammation and autoimmune diseases. sorrento's lead products are multiple late-stage biosimilar and biobetter antibodies, as well as clinical car-t therapies targeting solid tumors.
Sorrento Therapeutics Inc executives and other stock owners filed with the SEC include: